Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Remission rate in each group by DAS28-ESR, CDAI, and SDAI

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Remission rate PWs or HWs TCZ-SC group, n (%) csDMARDs-alone group, n (%) Odds ratio for
TCZ-SC group/csDMARDs-alone group
(95% confidence interval)
P value
(TCZ-SC group vs csDMARDs-alone group)
DAS28-ESR Overall 205.0 (67.9) 64.6 (21.7) 6.778 (4.508, 10.189) < 0.0001
PWs 104.1 (66.3) 39.7 (25.5) 5.689 (3.146, 10.287) < 0.0001
HWs 102.0 (70.3) 22.8 (16.1) 9.153 (4.814, 17.403) < 0.0001
CDAI Overall 125.5 (39.2) 58.5 (19.2) 2.549 (1.631, 3.982) < 0.0001
PWs 62.4 (37.3) 43.0 (27.1) 1.564 (0.860, 2.845) 0.1427
HWs 70.2 (45.9) 16.1 (11.1) 5.635 (2.757, 11.516) < 0.0001
SDAI Overall 132.1 (41.8) 57.4 (19.1) 2.855 (1.828, 4.458) < 0.0001
PWs 65.8 (40.1) 41.6 (26.5) 1.811 (0.991, 3.309) 0.0535
HWs 73.0 (48.1) 16.1 (11.3) 6.052 (2.981, 12.288) < 0.0001
  1. Adjusted odds ratio by the logistic regression model using last observation carried forward; adjusted-weight analysis by inverse probability treatment weighting method
  2. Remission was defined as DAS28-ESR < 2.6, CDAI ≤2.8, and SDAI ≤3.3
  3. CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, HW house worker, PW paid worker, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection